If our PAR techs were able to eliminate folk from the P3 trial who won't benefit from treatment then the results would be spectacularly successful with fantastic consequences both for the company and the treatment of other indications. That is why I'm interested in knowing where we are at with our understanding of why it works well for some people but not others and our ability to predict who will or won't benefit.
Chart, page-921
-
- There are more pages in this discussion • 3,382 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.80M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 29.0¢ | 24.0¢ | $969.3K | 3.648M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 34182 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 24689 | 1 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |